Amicus Therapeutics, Inc.
FOLD
Rangering i aksjer
#3694
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Aksjekurs
$14.49
Sist synkronisert: 2026-04-27
Markedsverdi
$4.55B
Endring (1 dag)
0.00%
Endring (1 år)
71.68%
Land
US
Handel Amicus Therapeutics, Inc. (FOLD)
Kategori
Healthcare
Antall utestående aksjer for Amicus Therapeutics, Inc. (FOLD)
Antall utestående aksjer per December 2025: 309.03M
Ifølge Amicus Therapeutics, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 309.03M. Ved slutten av December 2023 hadde selskapet 295.16M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Amicus Therapeutics, Inc. (FOLD) fra 2003 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 309.03M | 1.53% |
| 2024 | 304.38M | 3.12% |
| 2023 | 295.16M | 2.11% |
| 2022 | 289.06M | 6.50% |
| 2021 | 271.42M | 4.85% |
| 2020 | 258.87M | 7.67% |
| 2019 | 240.42M | 29.40% |
| 2018 | 185.79M | 21.15% |
| 2017 | 153.36M | 14.10% |
| 2016 | 134.40M | 22.27% |
| 2015 | 109.92M | 47.66% |
| 2014 | 74.44M | 45.15% |
| 2013 | 51.29M | 12.56% |
| 2012 | 45.57M | 31.81% |
| 2011 | 34.57M | 24.64% |
| 2010 | 27.73M | 22.59% |
| 2009 | 22.62M | 0.58% |
| 2008 | 22.49M | 69.95% |
| 2007 | 13.24M | 1,698.42% |
| 2006 | 735.97K | 79.41% |
| 2005 | 410.22K | 33.39% |
| 2004 | 307.54K | 0.00% |
| 2003 | 307.54K | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | -17.84% |
US
|
|
| 396.00M | 28.14% |
US
|
|
| 478.91M | 54.97% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -79.88% |
NL
|
